文献速递精神分裂症与精神病性障碍

未用药精神病患者部分多巴胺D2受体激动剂治疗前后的正电子发射断层显像多巴胺能活性:与精神病性症状及治疗反应的关系

Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response.
PubMed 文献 · Biol Psychiatry · 2021-09-10

本研究用四参数模型在62人(31例未用药首发精神病患者和31名对照)基线时行18F-DOPA正电子发射断层显像,其中15例患者6周后复查,临床随访6周(n=28)和6个月(n=15)。基线纹状体脱羧速率k3与基线阳性症状(p<.001)及6周症状改善(p=.006)相关,而组织参考法未发现多巴胺合成能力与症状或症状改善的关联。

要点

  • 基线纹状体脱羧速率k3较高与基线阳性症状较多相关(p<.001)。
  • 基线k3较高与6周后症状改善相关(p=.006)。
  • 组织参考法未发现多巴胺合成能力与症状或症状改善的关联。

核心结论

  • 基线纹状体脱羧速率与精神病性症状及治疗反应相关。
  • k3与治疗效应之间的强关联可能提示新的治疗策略。

研究设计与样本

  • 研究纳入62人(31例未用药首发精神病患者和31名对照),基线时行18F-DOPA正电子发射断层显像,其中15例患者6周后复查。
  • 临床随访在6周(n=28)和6个月(n=15)完成,症状用阳性与阴性症状量表评估。

主要发现

  • 高基线脱羧速率k3与基线阳性症状较多相关(p<.001)。
  • 高基线脱羧速率k3与6周后症状改善相关(p=.006)。
  • 亚区分析显示,壳核基线k3(p=.003)、伏隔核基线k3(p=.013)及伏隔核多巴胺合成能力值(p=.003)与精神病性症状相关。
  • 组织参考法未发现多巴胺合成能力与症状或症状改善的关联。
  • 两种方法均未显示组别或治疗对k3或多巴胺合成能力平均幅度的影响,而多巴胺合成变化与较高基线值相关,提示治疗可能存在效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dopamine activity has been associated with the response to antipsychotic treatment. Our study used a four-parameter model to test the association between the striatal decarboxylation rate of 18F-DOPA to 18F-dopamine (k3) and the effect of treatment on psychotic symptoms in antipsychotic-naïve patients with first-episode psychosis. We further explored the effect of treatment with a partial dopamine D2 receptor agonist (aripiprazole) on k3 and dopamine synthesis capacity (DSC) determined by the four-parameter model and by the conventional tissue reference method. METHODS: Sixty-two individuals (31 patients and 31 control subjects) underwent 18F-DOPA positron emission tomography at baseline, and 15 patients were re-examined after 6 weeks. Clinical re-examinations were completed after 6 weeks (n = 28) and 6 months (n = 15). Symptoms were evaluated with the Positive and Negative Syndrome Scale. RESULTS: High baseline decarboxylation rates (k3) were associated with more positive symptoms at baseline (p < .001) and with symptom improvement after 6 weeks (p = .006). Subregion analyses showed that baseline k3 for the putamen (p = .003) and nucleus accumbens (p = .013) and DSC values for the nucleus accumbens (p = .003) were associated with psychotic symptoms. The tissue reference method yielded no associations between DSC and symptoms or symptom improvement. Neither method revealed any effects of group or treatment on average magnitudes of k3 or DSC, whereas changes in dopamine synthesis were correlated with higher baseline values, implying a potential effect of treatment. CONCLUSIONS: Striatal decarboxylation rate at baseline was associated with psychotic symptoms and treatment response. The strong association between k3 and treatment effect potentially implicate on new treatment strategies.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sigvard AK, Nielsen MØ, Gjedde A, et al. Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response. Biol Psychiatry. 2021. PMID: 34743917. doi:10.1016/j.biopsych.2021.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。